Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91


Use of intravenous diuretics on day of discharge in adults hospitalized for heart failure.

Fazel R, Strait KM, Bikdeli B, Dharmarajan K, Krumholz HM.

J Card Fail. 2014 Sep;20(9):706-7. doi: 10.1016/j.cardfail.2014.06.354. Epub 2014 Jun 18. No abstract available.


Intravenous fluids in acute decompensated heart failure.

Bikdeli B, Strait KM, Dharmarajan K, Li SX, Mody P, Partovian C, Coca SG, Kim N, Horwitz LI, Testani JM, Krumholz HM.

JACC Heart Fail. 2015 Feb;3(2):127-33. doi: 10.1016/j.jchf.2014.09.007.


Contraindicated initiation of β-blocker therapy in patients hospitalized for heart failure.

Dharmarajan K, Masoudi FA, Spertus JA, Li SX, Krumholz HM.

JAMA Intern Med. 2013 Sep 9;173(16):1547-9. doi: 10.1001/jamainternmed.2013.7717. No abstract available.


Optimization of heart FailUre medical Treatment after hospital discharge according to left ventricUlaR Ejection fraction: the FUTURE survey.

Cohen Solal A, Leurs I, Assyag P, Beauvais F, Clerson P, Contre C, Thebaut JF, Genoun M; French National College of Cardiologists.

Arch Cardiovasc Dis. 2012 Jun-Jul;105(6-7):355-65. doi: 10.1016/j.acvd.2012.04.003. Epub 2012 Jun 28.


Is addition of vasodilators to loop diuretics of value in the care of hospitalized acute heart failure patients? Real-world evidence from a retrospective analysis of a large United States hospital database.

Gradman AH, Vekeman F, Eldar-Lissai A, Trahey A, Ong SH, Duh MS.

J Card Fail. 2014 Nov;20(11):853-63. doi: 10.1016/j.cardfail.2014.08.006. Epub 2014 Aug 21.


Hospital management of heart failure: improvement but still room for improvement at discharge...

Cohen-Solal A.

Arch Cardiovasc Dis. 2008 Apr;101(4):202-3. No abstract available.


National prescribing trends for heart failure medications in children.

Moffett BS, Price JF.

Congenit Heart Dis. 2015 Jan-Feb;10(1):78-85. doi: 10.1111/chd.12183. Epub 2014 Apr 11.


Cost-consequences of ultrafiltration for acute heart failure: a decision model analysis.

Bradley SM, Levy WC, Veenstra DL.

Circ Cardiovasc Qual Outcomes. 2009 Nov;2(6):566-73. doi: 10.1161/CIRCOUTCOMES.109.853556. Epub 2009 Nov 3.


Prescribing and emergency admissions for heart failure in greater Glasgow.

Davie AP, Morrison CE, Forrester JE, Mcmurray JJ.

J Card Fail. 1999 Mar;5(1):3-7.


Get With The Guidelines program participation, process of care, and outcome for Medicare patients hospitalized with heart failure.

Heidenreich PA, Hernandez AF, Yancy CW, Liang L, Peterson ED, Fonarow GC.

Circ Cardiovasc Qual Outcomes. 2012 Jan;5(1):37-43. doi: 10.1161/CIRCOUTCOMES.110.959122. Epub 2012 Jan 10.


Continuous versus bolus dosing of Furosemide for patients hospitalized for heart failure.

Allen LA, Turer AT, Dewald T, Stough WG, Cotter G, O'Connor CM.

Am J Cardiol. 2010 Jun 15;105(12):1794-7. doi: 10.1016/j.amjcard.2010.01.355. Epub 2010 Apr 27.


Evaluation of heart failure management in a Military Hospital.

Guiraudet O, Lambert de Crémeur G, Bonnevie L, Héno P, Pelletier C, Fraboulet R, Schiano P, Martin AC, Chenilleau MC, Delarbre D, Chanudet X.

Arch Cardiovasc Dis. 2008 Apr;101(4):235-41.


Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry.

Peacock WF, Costanzo MR, De Marco T, Lopatin M, Wynne J, Mills RM, Emerman CL; ADHERE Scientific Advisory Committee and Investigators.

Cardiology. 2009;113(1):12-9. doi: 10.1159/000164149. Epub 2008 Oct 17.


Effectiveness of continuous infusions of loop diuretics for severe heart failure.

Howard PA, Dunn MI.

J Cardiovasc Med (Hagerstown). 2006 Jan;7(1):5-10. Review.


The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries.

Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, Nodari S, Lam CS, Sato N, Shah AN, Gheorghiade M.

J Am Coll Cardiol. 2014 Apr 1;63(12):1123-33. doi: 10.1016/j.jacc.2013.11.053. Epub 2014 Feb 5.


Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.

Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators.

JAMA. 2007 Mar 28;297(12):1332-43. Epub 2007 Mar 25.


Predictors of delivery of hospital-based heart failure patient education: a report from OPTIMIZE-HF.

Albert NM, Fonarow GC, Abraham WT, Chiswell K, Stough WG, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy CW, Young JB.

J Card Fail. 2007 Apr;13(3):189-98.


Supplemental Content

Support Center